Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Shire plc (SHPGY)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: SHPGY
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Analysis - Latest Articles
by
most recent
|
most commented
Shire Seeks FDA Approval for Replagal
Dec 28
•
Zacks.com
•
Comment!
Ten Most Attractive FTSE 100 Stocks
Dec 20
•
Value Expectations
•
1 Comment
European Equities Lower on Momentum Change
Dec 17
•
The LFB
•
Comment!
Even as S&P 500 Rises, There Are Remaining Bright Spots Among DRs
Dec 3
•
Global Investing Editor
•
2 Comments
Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold
Nov 17
•
Mark Mitchell
•
Comment!
Genzyme: Haunted by Contamination
Nov 16
•
Zacks.com
•
Comment!
Developments for Parkinson's Disease Ignite Investor Enthusiasm
Nov 16
•
Michael Becker
•
5 Comments
Genzyme: Focusing on Lumizyme Approval
Oct 30
•
Mark Mitchell
•
Comment!
BioMed News: Antigenics, Shire, King Pharma, Delcath Systems
Oct 21
•
Mike Havrilla
•
29 Comments
Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited
Oct 6
•
Mark Mitchell
•
3 Comments
Sell Genzyme Near Term Due to Continued Manufacturing Challenges
Sep 24
•
Mark Mitchell
•
2 Comments
Tuesday Options Update: M, MBI, JDSU & SHPGY
Sep 22
•
Andrew Wilkinson
•
Comment!
Genzyme: Short Term Traders Are Throwing Out the Baby with the Bathwater
Sep 16
•
Ken Majmudar
•
Comment!
Clolar Decision Aside, Genzyme's Still a Near-Term Sell
Sep 2
•
Mark Mitchell
•
Comment!
Protalix Biotherapeutics: FDA Fast Track for Gaucher Treatment
Aug 26
•
BioPharma Investor
•
4 Comments
Biotech Dealmaking Takes a Summer Breather
Aug 23
•
The Burrill Report
•
Comment!
Closing Update for Wednesday, August 19: Stocks (and Crude) Scratch Back
Aug 19
•
Midnight Trader
•
1 Comment
Genzyme: More Negative News
Aug 18
•
Mark Mitchell
•
3 Comments
Genzyme Takes No Chances with Cerezyme Product
Aug 12
•
Mark Mitchell
•
Comment!
Genzyme’s Problems Continue
Aug 9
•
Zacks.com
•
1 Comment
Investing Outside the U.S.: 12 Stocks Worth Considering
Aug 6
•
Global Investing Editor
•
4 Comments
FDA Calendar Updates: Achillion Pharma, Roche, Genzyme, Protalix, Shire
Jul 31
•
Mike Havrilla
•
Comment!
FDA Calendar Updates: Schering-Plough, Shire, Elron Electronics, Cardium
Jul 28
•
Mike Havrilla
•
Comment!
Genzyme's Manufacturing Disruption Highlights Investment Opportunities
Jul 20
•
Michael Becker
•
4 Comments
U.K.'s Ten Best Stocks
Jul 15
•
Value Expectations
•
Comment!
FDA Calendar Updates: Oxford, Protalix, Spectrum, Shire
Jul 7
•
Mike Havrilla
•
1 Comment
Comparing Medicine’s Cost and Effectiveness
Jul 1
•
Eric Savitz
•
6 Comments
Pharma Announces $80B Reduction: Who Wins?
Jun 23
•
Larry Rothman
•
1 Comment
FDA Calendar Updates: Acusphere, AspenBio, Alkermes
May 19
•
Mike Havrilla
•
3 Comments
20 'Bathwater Babies' and 20 'Dogs with Fleas' Stocks for the Week
May 4
•
J Clinton Hill
•
2 Comments
Galleon's Q408: SPY Pays Off Alongside Reduced Equity Positions
Apr 21
•
Market Folly
•
Comment!
Where Might Genentech Investors Redeploy $47B?
Mar 16
•
Michael Becker
•
2 Comments
Corporate Flight from the U.S. - The Next Step?
Feb 27
•
Michael Cohen
•
7 Comments
20 'Babies with Bathwater' and 3 'Dogs with Fleas' for the Week
Feb 23
•
J Clinton Hill
•
1 Comment
Five Autism Stocks
Feb 16
•
Stockerblog
•
1 Comment
Autism in the News - and Stocks that Could Benefit
Feb 13
•
Stockerblog
•
2 Comments
What to Buy and Why: Barron's 2009 Roundtable, Part III
Jan 25
•
SA Editor Eli Hoffmann
•
19 Comments
Hedge Fund Tracking: Barry Rosenstein's Jana Partners, Q3 2008
Dec 24, 2008
•
Market Folly
•
3 Comments
Tuesday Options Update: VIX, XLF, YHOO, IRM, SHPGY, SKX, NTES, BBBY
Sep 23, 2008
•
Andrew Wilkinson
•
1 Comment
Shire May Have Another Winner in Purchase of Jerini
Jul 7, 2008
•
Eben Tessari
•
Comment!
Tuesday's Options Report: XLF, MS,LEH, GS, EWJ, SRZ, SHPGY, INTU
Mar 18, 2008
•
Andrew Wilkinson
•
Comment!
1
2
Next Page